期刊
HEMATOLOGICAL ONCOLOGY
卷 37, 期 4, 页码 487-489出版社
WILEY
DOI: 10.1002/hon.2671
关键词
blastic plasmacytoid dendritic cell neoplasm; bortezomib; lenalidomide; leukemia
We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemotherapy, we observed two complete responses and one clinical remission. Together with the encouraging literature data on the effects of lenalidomide and bortezomib on BPDCN cells, our results might prompt further investigations of this regimen's value in BPDCN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据